Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. 1977

W H Isacoff, and P F Morrison, and J Aroesty, and K L Willis, and J B Block, and T L Lincoln

The methotrexate (MTX)-plasma concentrations of 172 high-dose infusions over the range of 50-200 mg/kg were measured over the 72-hour period following the beginning of infusion. Pharmacokinetic analysis shows that a biexponential function adequately describes the plasma decay for all doses. The distribution of plasma clearances over the patient population at a given dose has been characterized by a biexponential clearance function and associated time-dependent variance. It is found that when each of the plasma clearance functions are scaled by their respective dose, the 1 SD bands about the resulting unit dose curves overlap throughout their time ranges and are therefore insignificantly different from one another. Thus, the plasma clearance over the 50-200-mg/kg range may be represented by a single dose-scalable biexponential model with half-lives of 1.8 +/- 0.1 and 8.4 +/- 0.5 hours. For a given maximum allowable plasma-MTX level (eg, 10(-5) M at 24 hours), the variance of the clearance distribution is shown to predict the expected fraction of patients who will require intensified rescue. Urinary clearance has been determined at 104 +/- 8 ml/minute over the dose range of 50-300 mg/kg and only 60% of the MTX was excreted in the urine by 72 hours.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

W H Isacoff, and P F Morrison, and J Aroesty, and K L Willis, and J B Block, and T L Lincoln
September 1980, Harefuah,
W H Isacoff, and P F Morrison, and J Aroesty, and K L Willis, and J B Block, and T L Lincoln
January 1980, Therapeutic drug monitoring,
W H Isacoff, and P F Morrison, and J Aroesty, and K L Willis, and J B Block, and T L Lincoln
June 1985, Cancer,
W H Isacoff, and P F Morrison, and J Aroesty, and K L Willis, and J B Block, and T L Lincoln
February 1978, Cancer treatment reports,
W H Isacoff, and P F Morrison, and J Aroesty, and K L Willis, and J B Block, and T L Lincoln
August 1984, Onkologie,
W H Isacoff, and P F Morrison, and J Aroesty, and K L Willis, and J B Block, and T L Lincoln
March 1978, Cancer treatment reports,
W H Isacoff, and P F Morrison, and J Aroesty, and K L Willis, and J B Block, and T L Lincoln
December 1980, The Journal of the Maine Medical Association,
W H Isacoff, and P F Morrison, and J Aroesty, and K L Willis, and J B Block, and T L Lincoln
June 1975, The New England journal of medicine,
W H Isacoff, and P F Morrison, and J Aroesty, and K L Willis, and J B Block, and T L Lincoln
January 1983, Pediatric pharmacology (New York, N.Y.),
W H Isacoff, and P F Morrison, and J Aroesty, and K L Willis, and J B Block, and T L Lincoln
September 1978, Cancer treatment reports,
Copied contents to your clipboard!